ArticleWorld journal of surgical oncology2026
Association of TREM1 expression with mTOR and DRP1 in gallbladder cancer: a study of 105 cases.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGallbladder cancer is highly aggressive and characterized by poor prognosis and limited treatment options. TREM1 (Triggering Receptor Expressed on Myeloid cells 1) may be involved in cancer inflammation and progression, but its relevance to gallbladder cancer is poorly understood. Expression of TREM1 in gallbladder cancer and correlation with mTOR activation, DRP1 upregulation, and clinical outcomes were investigated in the present study.
methodsImmunohistochemical staining of 105 gallbladder cancer specimens from patients receiving cholecystectomy, radical resection or palliative resection between 2015 and 2020 was conducted to show expression of TREM1, mTOR and DRP1. Data was analyzed by Chi-square test, Kaplan-Meier survival curve, Cox regression model and correlation analyses.
resultsHigh TREM1 expression was observed in 63% gallbladder cancer cases and was linked to a more advanced T stage (p = 0.015), the presence of lymph node metastasis (p = 0.041) and an elevated TNM stage (p = 0.006). Positive correlations were shown between TREM1 and mTOR (p < 0.001) and between TREM1 and DRP1 (p < 0.001). Patients with high TREM1 expression had shorter overall survival than those with low expression (median 18 months vs. 50 months, p < 0.001). TREM1 was identified by multivariate analysis as an independent prognostic factor (HR = 1.838, 95% CI: 1.038-3.252, p = 0.037).
conclusionsImmunohistochemical analysis demonstrated that TREM1 is overexpressed in gallbladder cancer and positively correlated with mTOR and DRP1 expression. TREM1 may be a suitable prognostic biomarker and therapeutic target in gallbladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.